TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| CNA, other RN unions clamor for "super union," blast opponents Leaders and members of three big U.S. nurses’ organizations, including the always feisty California Nurses Association, took aim Tuesday at a host of enemies at a San Francisco conclave, including -- implicitly at least -- internal opponents of a proposed merger linking the groups. feeds.bizjournals.com |
Navigating Medicare With Pros A growing number of affluent Americans are turning to their financial advisers for guidance navigating the Medicare maze. online.barrons.com |
Getting Health Coverage After Cobra With eligibility for a government subsidy for Cobra premiums due to expire, some laid-off workers are puzzled about what to do next. online.barrons.com |
Merck Starts China Trial of Cancer Vaccine ChinaBio Today submits: Merck KGaA (MRK) of Germany will conduct a multi-national Phase III clinical trial of the therapeutic cancer vaccine Stimuvax in Asian patients. The trial will enroll 420 patients with advanced non-small cell lung cancer (NSCLC) in five Asian countries: China, Hong Kong, South Korea, Singapore and Taiwan. In its double-blind Phase IIb trial, the addition of Stimuvax to best supporting care extended median survival from 13.3 months to 30.6 months, an excellent result in a particularly difficult form of cancer.Complete Story » seekingalpha.com |
Biogen Idec’s Tysabri Continues to Grow in Popularity but Poses Some Risks Zacks.com submits: Last week, the European Medicines Agency (EMEA) finalized a review of Biogen Idec’s (BIIB) Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML) associated with the prolonged use of the drug. PML is a rare brain infection caused by the JC virus. The agency’s Committee for Medicinal Products for Human Use (CHMP) arrived at the conclusion that the risk of a patient developing PML increases after having taken the drug for two years or more, though the risk remains low. However, the benefits of the drug outweigh its risks.Complete Story » seekingalpha.com |